AbbVie (ABBV) Secures EU Approval for Pediatric SKYRIZI

AbbVie (ABBV) announced June 23, 2026, that the European Commission approved SKYRIZI (risankizumab) for treating moderate to severe plaque psoriasis in children and adolescents aged 6 and older. This approval expands the drug's label, previously cleared for adult use, into the pediatric market across the European Union. The decision follows positive data from the Phase 3 PEDIATRIC trial, which demonstrated the efficacy and safety of SKYRIZI in this younger patient population. This regulatory milestone allows AbbVie to offer SKYRIZI, an interleukin-23 (IL-23) inhibitor, to a broader demographic, potentially increasing its market share in the dermatology segment.